Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry and Efficacy of Iodine-131 Anti-B1 Antibody in Refractory NHL
NCT01224821Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 1995
- Primary completion
- Nov 1997
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of iodine i 131 tositumomab in non-Hodgkin lymphoma (NHL), sponsored by GSK. Primary endpoint: Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites. Started Dec 1995; status: completed.
02
Drugs
iodine i 131 tositumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01224821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224821.